Silence Therapeutics News

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

May 1 16:42 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 29 08:38 ET

Silence Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Apr 15 07:03 ET

Silence Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Richard Ian Griffiths(16.9%),Ora Capital Limited(7.8%)

Mar 27 17:10 ET

Silence Therapeutics | 20-F: Registration statement / Annual report / Transition report

Mar 13 08:58 ET

Silence Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Mar 13 07:13 ET

Silence Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Feb 23 08:14 ET

Silence Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Lombard Odier Asset Management (USA) Corp(10.4%)

Feb 14 09:57 ET

Silence Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Deep Track Capital, LP(5.43%),Deep Track Biotechnology Master Fund, Ltd.(5.43%), etc.

Feb 14 08:57 ET

Silence Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-THE GOLDMAN SACHS GROUP, INC.(2.2 %),GOLDMAN SACHS & CO. LLC(2.2 %)

Feb 12 18:20 ET

Silence Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Invus Public Equities, L.P.(7.8%),Invus Public Equities Advisors, LLC(7.8%), etc.

Feb 9 17:10 ET

Silence Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Feb 6 13:57 ET

Silence Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Dec 1, 2023 07:00 ET

Silence Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Nov 14, 2023 07:00 ET

Silence Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Nov 1, 2023 07:00 ET

Silence Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Invus Public Equities, L.P.(6.8%),Invus Public Equities Advisors, LLC(6.8%), etc.

Sep 1, 2023 16:12 ET

Silence Therapeutics | 6-K/A: Report of foreign private issuer (related to financial reporting)

Aug 29, 2023 16:01 ET

Silence Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Aug 16, 2023 07:00 ET

Silence Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Richard Ian Griffiths(26.58%)

Aug 14, 2023 17:01 ET

Silence Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Aug 1, 2023 16:31 ET